AGOC
Abstract: INTEGRATE IIa: A randomised, double-blind, phase III study of regorafenib versus placebo in refractory advanced gastro-oesophageal cancer (AGOC)—A study led by the Australasian Gastro-intestinal Trials Group (AGITG).

Released: January 25, 2023

Expiration: January 24, 2024

Nick Pavlakis
Nick Pavlakis, PhD, MBBS, FRACP

Activity

Progress
1
Course Completed